1. Introduction {#sec1}
===============

Coronavirus disease 2019 (COVID-19) is a new viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly designated as 2019-nCoV), a novel betacoronavirus firstly identified during a burst of respiratory illness cases in Wuhan City, Hubei Province, China ([@bib25]; [@bib78]; [@bib19]; [@bib77]). In a few weeks the disease became a pandemic with 5,593,631 cases and 353,334 confirmed deaths reported as of May 28, ([@bib67]). A wealth of recent data highlights the disregulated immune response and its inflammatory component as the main casue of morbidity and mortality ([@bib5]; [@bib6]; [@bib10]; [@bib14]; [@bib16]; [@bib27]; [@bib44]; [@bib56]; [@bib74]; [@bib77]; [@bib80]), undescoring the need of a better comprehension of the early events that shape the virus-host reaction in COVID-19.

In ths scenario, it is worth recalling that the components of the innate immune system act as first responder for the detection and clearance of viral infections. Innate immune cells secrete proinflammatory cytokines which inhibit viral replication, stimulate the adaptive immune response, and recruit other immune cells to the site of infection. The implementation of an efficient immune response is a crucial aspect in the control and clearance of virally infected cells. Indeed, innate and adaptive immune responses cooperate to protect the host against microbial infections ([@bib23]; [@bib62]; [@bib24]).

NK cells are innate immune cells whose function is critical in the first-line of defense against against viral, bacterial and parasitic infection ([@bib24]) as well as in tumor surveillance ([@bib60]; [@bib71]), and their functional exhaustion has been correlated to disease progression ([@bib79]). Furthermore, NK cells are considered a pivotal player in integating innate and adaptive immune reponses ([@bib62]; [@bib32]). For these reasons, NK cells have been extensively studied in different setting of infectious diseases that have represented, so far, major health issues worldwide such as HBV, HCV and HIV ([@bib50], [@bib42]; [@bib28]; [@bib57]).

COVID-19 has spread rapidly throughout the globe and is one of the hardest challenge that modern science has to face. At the moment of writing this manuscript, a growing body of data are emerging on variation in the number and function of NK cells during SARS-CoV-2 infection, correlating it with the severity of clinical presentation and outcome ([@bib75]; [@bib66]; [@bib81]). However, the functional implications of this observation need to be elucidated.

NK cells are activated by a plethora of cytokines including IL-2, IL-12, IL-15 and type I INF ([@bib48], [@bib49]; [@bib58]; [@bib48], [@bib49]; [@bib35]; [@bib59]; [@bib51]); once triggered, they produce several chemokines such as CCL3/MIP1α, CCL4/MIP1β CCL5/RANTES, and cytokines such as interferon-γ (IFN-γ), tumor necrosis factor (TNF), and granulocyte/macrophage colony-stimulating factor (GM-CSF) ([@bib36]). These soluble factors play not only an important regulatory role in hematopoiesis, but also contribute to either priming or taking part to the activation of cellular networks.

In fact, it has been shown that NK cells are engaged in an active and bi-directional cross-talk with autologous dendritic cells (DCs) through a process that requires both NK-cell --DC-cell interactions and secretion of specific cytokines ([@bib23]; [@bib40]; [@bib15]). Furthermore, monocytes/macrophages and neutrophils have been shown to regulate the recruitment and the activation of NK cells, which, in turn, can eliminate over-stimulated macrophages ([@bib64]; [@bib37]). This "mènage à trois" involves direct reciprocal interactions as well as positive amplification loops mediated by cell-derived cytokines, with the aim of inducing IFN-γ production by NK cells ([@bib64]; [@bib37]).

The final outcome of these synergic interactions is the coordination and optimization of both innate and adaptive immunity in response to inflammatory stimuli such as viral infections at tissue sites ([@bib40]; [@bib39]; [@bib30]). In this highly dynamic scenario, NK cells likely configure as important players in determining the quality of the immune responses in COVID-19 patients, critically balancing the direct response to the virus -- by eliminating infected cells -- and the systemic inflammatory response -- by killing DC, monoctyes and T-cells ([@bib10]; [@bib27]; [@bib54]). The loss of this balance appears to be critical during COVID-19 since the overactive cytokine response that typifies the more severe cases rapidly leads to increased risk of vascular hyperpermeability, multiorgan failure, and eventually death ([@bib22]).

2. NK cells as defence against viruses {#sec2}
======================================

NK cells are known to be an efficient protective shield against virus infections. First experimental evidence emerged in the late 1980s reporting severe and recurrent herpes virus infections in a young patient with NK cell deficiency ([@bib4]). The fact that NK cells do not need a prior antigen sensitization makes them ready to fight against pathogens starting from the early phases of innate immune responses through several effector functions controlled by a dynamic balance between inhibitory and activating NK cell receptors (NKRs) ([@bib39]).

Indeed, NK cells are able to lyse "non-self" cellular targets while sparing normal cells that express adequate levels of "self" major histocompatibility complex of class I (MHC-I) molecules. This cytolytic function is regulated by a heterogeneous family of inhibitory NKRs (iNKRs) that bind specifically to either classical or non-classical human leukocyte antigen (HLA) alleles ([@bib46]). Diminution or absence of expression of HLA-I molecules on the surface of virally infected cells results in reduced engagement of iNKRs which, in turns, allow a large group of activating NKRs (aNKRs) to trigger cytotoxicity.

The "on signal" exerted by aNKRs to trigger NK cell killing depends on the induced expression of putative ligands for activating receptors on virally infected target cells ([@bib46]). The recognition of these specific ligands is required for the engagement of aNKR-mediated downstream pathways associated with the NK cell release of lytic granules ([@bib46]). The absence of NK cells results in a significant increased susceptibility to infection ([@bib2]; [@bib55]), increasing viral titers and mortality of HSV-2 infected mice. As a critical component of the innate immune response, NK cells act inducing the cytolysis of infected cells ([@bib61]; [@bib71], [@bib72]) and the release of inflammatory cytokines as INF-γ ([@bib45]; [@bib55]).

Although NK cells are primarily activated by IL-15 released from DCs upon an inflammatory stimulus such as type I-INFs ([@bib29]; [@bib3]), other adoptive transfer strategies have been proposed. It has been shown that IFN receptors are not required on NK cells for their activation in the context of Murine Citomegalovirus infection ([@bib17]). Moreover, it has been demonstrated that NK cells may be primed to produce IFN-γ by monocytes via IL-8. Indeed, the innate NK response may be dependent from monocytes, as suggested by the fact that CCR2^−/−^ mouse model, having deficient inflammatory monocyte recruitment, display a significant decrease of IFN-γ production by NK cells ([@bib20]). The central role of monocytes in NK activation is well described for example in HCV infection, in which in-vitro depletion of inflammatory monocytes from human PBMCs suppressed NK cell responses ([@bib73]; [@bib52]).

2.1. NK cells in respiratory infections {#sec2.1}
---------------------------------------

Extensive evidence exists that early innate functions of NK cells are essential and beneficial in immune defense against respiratory viral infections. These activities include antiviral cytokine production (e.g.,IFN-γ) and lysis of virus-infected cells. At low to intermediate inoculum doses of respiratory syncytial virus (RSV), Sendai virus (parainfluenza virus), and influenza A virus (IAV in mice and hamsters, the activities of NK cells can reduce viral burden and protect from fatal disease ([@bib63]; [@bib12]).

In the course of an experimental influenza infection of pigs, type I IFN is detected in the bronchoalveolar secretions together with TNF-α, and IL-1 and IL−6. The IFN response starts within 12 h post inoculation, peaks within 18--24 h along with maximal viral replication. In addition, the level of lung pro-inflammatory cytokines correlates with the intensity of clinical signs and neuthrophil infiltrate in the bronchoalveolar lavage fluid ([@bib9]).

The relative contributions of resident vs. circulating NK cells specifically recruited into the lung to pathogen clearance remain undefined.

Nevertheless, the anergic status of human-lung-resident NK cells during homeostasis ([@bib33]) suggests that persistence of highly active NK cells in the lung may be more harmful than beneficial, potentially worsening organ injury. Of note, NK cells can potentiate lung injury, reducing survival of mice during respiratory infections that are characterized by higher titers of virus and strong inflammatory responses. A heightened NK-cell activity, resulting in increased IFN-γ production, serves to exhacerbate lung inflammation during both IAV and RSV infections ([@bib12]; [@bib1]). Moreover, elevated IL-2 and IL-18 amplify this detrimental process, favouring interstitial pneumonia ([@bib43]; [@bib34]). Irreversible lung damage by NK cells may be more than just an unfortunate side effect of IFN-γ production, as the robust cytolytic elimination of virus-infected airway epithelial cells by NK cells is a critical antiviral function that may exceed the functional and regenerative capacity of the lung.

2.2. NK cells in non-COVID-19 coronavirus infections {#sec2.2}
----------------------------------------------------

As discussed above, NK cells are involved in viral infection control in animal models and humans ([@bib63]). However, to the best of our knowledge, the interplay between NK cells and SARS has been scarcely described.

Hua et al. proved that nasal inoculation of Murine Hepatitis Virus Strain 1 (MHV-1, capable to reproduce a clinical model of SARS in Mice), primes NK activation and increase pulmonary recruitment of Ly6C + inflammatory monocytes via type I INF signaling, generating a innate immune-mediated control toward second coronavirus infection ([@bib18]).

NK cell cytotoxicity is regulated by a multitude of receptors including CD158b, which binds to MHC-I expressed on target cells ([@bib46]; [@bib23]). [@bib68] reported that, in patients with SARS, the total number of NK cells, as well as the total number and percentage of CD158b^+^ NK cells, were significantly lower than patients with interstitial pneumonia caused by *Mycoplasma pneumoniae* and than control subjects. The number of NK cells and CD158b^+^ NK cells remained low for the entire disease course and began to recover after the 40th day of the disease. In severe SARS cases, all three parameters were significantly lower than those in mild cases of SARS. No significant differences were found between the group with mild SARS and that with *M. pneumoniae* infection ([@bib68]).

How the SARS virus alters the number and function of NK cells needs to be elucidated. The mechanism of CD158b down-regulation in patients with SARS is still under investigation, and, according to [@bib68], two possible mechanisms might underlie under this process: (i) CD158b is detached from the NK surface and becomes soluble in the serum; and/or (ii) the expression of CD158b is down-regulated at the transcriptional or translational level. Concerning the reduction in total NK number, possible explations may be: (i) NK cytolysis after killing the infected target cells; and/or (ii) redistribution to targeted organs (e.g., the lung).

2.3. NK cells in COVID-19 {#sec2.3}
-------------------------

Several evidences support the fact that lymphopenia is associated with severe clinical presentation of COVID-19. Specifically, T cell- and CD8^+^ T cell-count were reduced in COVID-19 patients as compared to non-infected cases and, among COVID-19 patients, severe cases presented significantly lower counts as compared to mild cases ([@bib75], [@bib10], [@bib21] [@bib65]; [@bib81]). Similarly, NK cell count reduces remarkably during Sars-Cov-2 infection, predominantely in critically ill patients ([@bib66]; [@bib75]; [@bib16]). This is is consistent with previous findings in SARS as outlined above ([@bib68]) and it is conceivable that this finding is due to NK sequestration into target organs, e.g. the lung. However, it is unclear at this time if this decrease is due to NK cell redistribution in infected sites or cell death.

In addition, a very intersting mechanism of T and NK cell exhaustion has been hypothesized by [@bib75]. In their work, the authors observe that the NK group 2 member A (NKG2A) receptor, which transduces inhibitory signalling and suppresses T-cell and NK cytokine secretion and cytotoxic function, is overexpressed in COVID-19 patients as compared to healthy controls, while the percentage of T and NK cells expressing the activation markers CD107a, IFNɣ, IL-2, and TNFɑ was significanly lower ([@bib75]). Taken together, these data indicate that patients with severe COVID-19 have a severely compromised innate immune response likely due to a functional exhaustion of peripheral CD8^+^ T and NK cells ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Hypothesized double-sided mechanism of Sars-Cov-2 and NK cells interaction. In case of effective immune innate response, NK cells express the activation marker CD107a and release IFNɣ, IL-2, and TNFɑ (right side). In case of exhaustion, NK cells overexpress the inhibitory NKG2A receptor, which suppress T-cell and NK cytotoxic function, favoring a pro-inflammatory condition (left side).Fig. 1

Loss of NK cell effector functions is the most prominent immunological feature of the macrophage activation syndrome (also reffered to as hemophagocytic lymphohistiocytosis, HLH), a condition that can be triggered by infections and that closely resembles the "hyperferritinemic syndrome" that Shoenfeld et al. compare to Sars-CoV-2-related cytokine storm ([@bib53]). Similarly to what happens in HLH, local and systemic inflammation contributes to reduce NK cell effector functions; specifically, elevated IL-6 and IL-10 levels (as the ones observed in COVID-19) are capable to inhibit NK cytotoxic activity as the expression of PERF and granzyme B). Moreover, IL-6 may further impair NK activity by reducing the expression of NKG2D, important in the killing of infected cells ([@bib47]).

Xiong et al. showed that several upregulated genes in PBMCs from COVID-19 patients are involved in the apoptosis pathways, suggesting lymphopenia may be due to SARS-CoV-2-mediated apoptosis, supporting therefore the cell-death hypothesis ([@bib69]).

By contrast, in favour to the target-site sequestration mechanism, scRNA-seq analysis of bronchoalveolar lavage fluid (BALF) samples from COVID-19 patients (three severe and three mild cases) allowed detection of higher amounts of NK cells in COVID-19 patients as compared to controls, suggesting NK cell trafficking into the lungs ([@bib26]). Finally, bulk RNA-seq on BALF from eight COVID-19 cases, found a significant decrease in resting NK cells in COVID-19 patients compared to healthy controls, but no changes in the number of activated NK cells ([@bib76]).

The discrepancies between these two studies could be explained by the fact that in the cohort analyzed by [@bib76], the time of sampling was closer to the day of symptoms onset, suggesting that the trafficking of NK cells into the lungs might occur in a time-dependent fashion, preferenatially in the stages of infection.

Taken together these data, although preliminary, suggest that upon SARS-CoV-2 infection, NK cells exit the peripheral blood, traffick into to the lung where potentially contribuite to local inflammation and injury. By constrast, NK cells that remain in the circulation display an exhausted phenotype that facilitate virus spread to other organs ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 2Hypothesized opposite behavior of circulating vs. lung-resident NK cells during COVID-19: NK cells that remain in the circulation display an exhausted phenotype that facilitate virus spread while NK cells that exit blood and traffic into the lung contribute to local inflammation and tissue damage.Fig. 2

The rationale of using NK cells and/or NK cell modulation in COVID 19 disease has to be based on the timing of therapeutic "fine tuning" of NK cells, which would likely determine the balance between their beneficial antiviral and detrimental pathologic action. During Sendai parainfluenza virus infection in mice, early infusion of NK cells partially controlled low-dose inoculum infection, whereas therapy initiation at a later stage of infection increased viral replication and associated morbidity ([@bib41]). Similarly, patient-specific factors are likely to impact the efficacy of NK-cell based therapeutics, as severe SARS-CoV-2 infection is associated with hypoxia and elevated IL-6 ([@bib10]), which can significantly impair the function of NK cells ([@bib11]). The potential role of elevated IL-6 in poor outcome of SARS-CoV-2 infections has even led to clinical trials investigating the utility of drugs that inhibit IL-6 (e.g., tocilizumab; <https://clinicaltrials.gov/ct2/show/NCT04335071>) or JAK signaling (e.g., tofacitinib; <https://clinicaltrials.gov/ct2/show/NCT04332042>) in the treatment of critical illness in SARS-CoV-2 patients. Some preliminary data in this regard is already available in the published literature ([@bib31]; [@bib13]; [@bib70]; [@bib8]; [@bib38]; [@bib7]). Of note, tofacitinib and related JAK-inhibitors can reduce the number and function of NK cells, highlighting how clinical benefit of such drugs could stem, in part, from depletion of potentially pathogenic NK cells.

3. Conclusions {#sec3}
==============

COVID-19 is characterized by substantial components of what is considered to be a special dysregulated and imbalanced innate immune response to SARS-CoV-2 infection. Of note, we do not really know at the moment the features of a proficient and effective innate immune response towrd SARS-CoV-2. A likely solution to this impelling problem is to assess patient populations that, up until now, have been relatively overlooked. In fact, the vast majority of COVID-19 studies have focused on patients with serious/severe disease.

A critical part of our understanding of SARS-CoV-2 infection, and potentially useful to identify a coordinated, successful immune response, would be to assess COVID-19 patients with mild disease, not requiring hospitalization. A longitudinal study comparing the immune responses of hospitalized versus non-hospitalized patients would be pivotal to delineate this relevant insight. Such studies will provide a path as to how we need to modulate the immune response for maximum benefit and to improve patient recovery. Undestanding in more detail the interface between innate immunity, adaptive immuty and SARS-CoV-2 will be instrumetal in increasing favourable patient outcome and helping to design future immune interventions aimed to modulatee disease impact and/or to prevent disease occurrence (such as vaccines).
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